Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis and, increasingly, for the therapy of diseases. Radiopharmaceuticals may be given to the patient in several different ways. For example, they may be given by mouth, given by injection, or placed into the eye or into the bladder. The global radiopharmaceuticals market is projected to rise by USD 7.5 billion by 2029, according to the latest market study results. It is anticipated to expand at a CAGR of 9.7 percent during the forecast period.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global radiopharmaceuticals market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors' approaches.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, production method, application, end user, and region. The global market for radiopharmaceuticals can be segmented by product: diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals. According to the research, the diagnostic radiopharmaceuticals segment had the largest share in the global radiopharmaceuticals market. Radiopharmaceuticals market is further segmented by production method: nuclear reactor, cyclotron, generator. In 2022, the nuclear reactor segment made up the largest share of revenue generated by the radiopharmaceuticals market. Based on application, the radiopharmaceuticals market is segmented into: cardiovascular diseases, neurological disorders, oncology, others. Among these, the oncology segment was accounted for the highest revenue generator in 2022. On the basis of end user, the radiopharmaceuticals market also can be divided into: diagnostic centers, hospitals, research institutes, others. The hospitals segment captured the largest share of the market in 2022. Radiopharmaceuticals market by region is categorized into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America.
The diagnostic radiopharmaceuticals market is further segmented into SPECT radiopharmaceuticals, PET radiopharmaceuticals, others. The latest analysis indicates that the SPECT radiopharmaceuticals segment occupied the largest share of this market in 2022 and is expected to draw the highest demand in coming years. Furthermore, the therapeutic radiopharmaceuticals market has been categorized into beta emitters, alpha emitters, brachytherapy seeds, others. Globally, the beta emitters segment made up the largest share of the radiopharmaceuticals market.
Market Segmentation
By product: diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals
By production method: nuclear reactor, cyclotron, generator
By application: cardiovascular diseases, neurological disorders, oncology, others
By end user: diagnostic centers, hospitals, research institutes, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The report explores the recent developments and profiles of key vendors in the Global Radiopharmaceuticals Market, including Advanced Accelerator Applications S.A. (Novartis AG), Australian Nuclear Science and Technology Organisation (ANSTO), Bayer AG, Bracco S.p.A., Cardinal Health, Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, ECZACIBASI-MONROL Nuclear Products Co., Eli Lilly and Company, GE Healthcare, IBA Radiopharma Solutions (Ion Beam Applications SA), IRE - IRE ELiT, Jubilant Life Sciences Ltd., Lantheus Holdings, Inc., Navidea Biopharmaceutical, Inc., Nordion, Inc., NTP Radioisotopes SOC Ltd., Siemens Healthineers AG, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Scope of the Report
• To analyze and forecast the market size of the global radiopharmaceuticals market.
• To classify and forecast the global radiopharmaceuticals market based on product, production method, application, end user, region.
• To identify drivers and challenges for the global radiopharmaceuticals market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global radiopharmaceuticals market.
• To identify and analyze the profile of leading players operating in the global radiopharmaceuticals market.
Why Choose This Report
• Gain a reliable outlook of the global radiopharmaceuticals market forecasts from 2023 to 2029 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.
TABLE OF CONTENTS
FIGURES AND TABLES
PART 1. INTRODUCTION
· Report description
· Objectives of the study
· Market segment
· Years considered for the report
· Currency
· Key target audience
PART 2. METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
· Introduction
· Drivers
· Restraints
PART 5. MARKET BREAKDOWN BY PRODUCT
· Diagnostic radiopharmaceuticals
· Therapeutic radiopharmaceuticals
PART 6. MARKET BREAKDOWN BY PRODUCTION METHOD
· Nuclear reactor
· Cyclotron
· Generator
PART 7. MARKET BREAKDOWN BY APPLICATION
· Cardiovascular diseases
· Neurological disorders
· Oncology
· Others
PART 8. MARKET BREAKDOWN BY END USER
· Diagnostic centers
· Hospitals
· Research institutes
· Others
PART 9. MARKET BREAKDOWN BY REGION
· North America
· Europe
· Asia-Pacific
· MEA (Middle East and Africa)
· Latin America
PART 10. KEY COMPANIES
· Advanced Accelerator Applications S.A. (Novartis AG)
· Australian Nuclear Science and Technology Organisation (ANSTO)
· Bayer AG
· Bracco S.p.A.
· Cardinal Health, Inc.
· Eckert & Ziegler Strahlen- und Medizintechnik AG
· ECZACIBASI-MONROL Nuclear Products Co.
· Eli Lilly and Company
· GE Healthcare
· IBA Radiopharma Solutions (Ion Beam Applications SA)
· IRE - IRE ELiT
· Jubilant Life Sciences Ltd.
· Lantheus Holdings, Inc.
· Navidea Biopharmaceutical, Inc.
· Nordion, Inc.
· NTP Radioisotopes SOC Ltd.
· Siemens Healthineers AG
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER
The global Radiopharmaceuticals for Therapeutic market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market...
The global Therapeutic Radiopharmaceuticals market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market pla...
The global Diagnostic Radiopharmaceuticals & Contrast Media market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will...
Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis and, increasingly, for the therapy of diseases. Radiopharmaceuticals may be given to the patient in sever...
Overview of the Global Therapeutic Radiopharmaceuticals Market:The report discusses everything a marketer requires before investing in the global Therapeutic Radiopharmaceuticals Market during the forecast period 2023-2030. It provides detailed insight into current trends,...
Overview of the Global Radiopharmaceuticals in Nuclear Medical Market:The report discusses everything a marketer requires before investing in the global Radiopharmaceuticals in Nuclear Medical Market during the forecast period 2022-2029. It provides detailed insight into c...
Overview of the Global Radiopharmaceuticals in Nuclear Medicine Market:The report discusses everything a marketer requires before investing in the global Radiopharmaceuticals in Nuclear Medicine Market during the forecast period 2022-2029. It provides detailed insight into...
Nuclear medicine is a medical specialty which uses radioactive tracers to diagnose and treat disease. Specially designed cameras allow doctors to track the circulation, uptake and excretion of these radioactive tracers. Garnering a CAGR of 10.4% from 2022 to 2028, the global nuclear medicine & radio...
Radiation therapy is the treatment of cancer and other diseases with radiation. Radiation in various forms is used to kill the cancer cells by preventing them from multiplying. Therapeutic radiology may be used to cure or control cancer, or to alleviate some of the symptoms associated with cancer. G...
Overview of the Europe Radiopharmaceuticals Market:The report discusses everything a marketer requires before investing in the Europe Radiopharmaceuticals Market during the forecast period 2022-2029. It provides detailed insight into current trends, market shares, market s...